Fair Value Measurements, Part 2 (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Total realized/unrealized gains (losses)
Total amount of unrealized gains (losses) for the period included in other comprehensive loss attributable to the change in fair market value of related assets still held at the reporting date	$ 192	$ 68	$ 8
Auction Rate Securities [Member]
Summary of activities in financial instruments with significant Level 3 inputs [Roll Forward]
Balance at beginning of period	2,208	3,240
Transfers into Level 3	0	0
Total realized/unrealized gains (losses)
Included in net income (loss)	0	0
Included in comprehensive income (loss)	192	68
Settlements	(2,400)	(1,100)
Balance at end of period	0	2,208
Total amount of unrealized gains (losses) for the period included in other comprehensive loss attributable to the change in fair market value of related assets still held at the reporting date	0	0
Fair Value Measurements, Quantitative Information
Fair Value		2,208
Valuation technique		Discounted cash flow model
Azedra commercialization [Member]
Fair Value Measurements, Quantitative Information
Period of milestone expected achievement	2018	2017
Fair Value	2,300	2,300
Valuation technique	Probability adjusted discounted cash flow model	Probability adjusted discounted cash flow model
Discount Rate	10.00%	10.00%
Probability of success	40.00%	40.00%
MIP-1095 commercialization [Member]
Fair Value Measurements, Quantitative Information
Period of milestone expected achievement	2023	2021
Fair Value	400	500
Valuation technique	Probability adjusted discounted cash flow model	Probability adjusted discounted cash flow model
Discount Rate	10.00%	10.00%
Probability of success	19.00%	19.00%
Net sales targets [Member]
Fair Value Measurements, Quantitative Information
Fair Value	10,700	10,900
Valuation technique	Monte-Carlo simulation	Monte-Carlo simulation
Discount Rate		12.50%
Contingent Consideration Liability [Member]
Summary of activities in financial instruments with significant Level 3 inputs [Roll Forward]
Balance at beginning of period	15,700	15,700		0
Total realized/unrealized gains (losses)
Fair value of contingent consideration - acquisition of Molecular Insight	0	15,900
Fair value change to contingent consideration included in net income (loss)	1,500	(200)
Balance at end of period	17,200	15,700		0
Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for assets or liabilities held at the end of the reporting period	1,500	(200)
1404 commercialization [Member]
Fair Value Measurements, Quantitative Information
Period of milestone expected achievement	2019	2018
Fair Value	$ 3,800	$ 2,000
Valuation technique	Probability adjusted discounted cash flow model	Probability adjusted discounted cash flow model
Discount Rate	10.00%	10.00%
Probability of success	59.00%	31.00%
Minimum [Member] | Auction Rate Securities [Member]
Fair Value Measurements, Quantitative Information
Redemption period		5 years
Discount Rate		0.25%
Minimum [Member] | Net sales targets [Member]
Fair Value Measurements, Quantitative Information
Period of milestone expected achievement	2019	2018
Discount Rate	3.50%
Probability of success	19.00%	19.00%
Maximum [Member] | Auction Rate Securities [Member]
Fair Value Measurements, Quantitative Information
Redemption period		15 years
Discount Rate		3.00%
Maximum [Member] | Net sales targets [Member]
Fair Value Measurements, Quantitative Information
Period of milestone expected achievement	2026	2022
Discount Rate	12.00%
Probability of success	59.00%	40.00%
Weighted average [Member] | Auction Rate Securities [Member]
Fair Value Measurements, Quantitative Information
Redemption period		6 years
Discount Rate		1.55%
Weighted average [Member] | Net sales targets [Member]
Fair Value Measurements, Quantitative Information
Probability of success	37.40%	32.80%